Shares of Sarepta Therapeutics, Inc. (SRPT) traded over 2% lower in afternoon trade on Friday after the company said it has ...

NBE Therapeutics CEO Jean Engela stated: "This investment in a new, cutting-edge research centre underscores our strong ...

Learn more about whether Corcept Therapeutics Incorporated or GSK plc is a better investment based on AAII's A+ Investor ...

Register for free now. Corcept Therapeutics Incorporated CORT announced on Monday that the ROSELLA Phase 3 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian ...

MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026MZE782 Phase 1 Healthy Volunteer ...

Also Read: Edgewise Therapeutics’ Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease In September 2024, the company announced topline data from ...

Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten offering of 9,935,419 shares of its common stock at an ...

Axsome Therapeutics said it's dopamine and norepinephrine reuptake inhibitor solriamfetol (Sunosi), approved for excessive daytime sleepiness, failed to reduce symptoms of major depressive disorder in ...

Two startups focused on individual coverage health reimbursement arrangement plans received funding this week.

ATLANTA, March 31, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company”), a development-stage biotechnology company developing new medicines to treat pain and ...

Cash and cash receivable balance of $20.9 million as of December 31, 2024, expected to fund operations, including clinical activities into 2027Strengthened cash position expected to support ...

MT-601, Marker's lead MAR-T cell therapy, is being evaluated in the nationwide multicenter Phase 1 APOLLO study ( clinicaltrials.gov identifier: NCT05798897) in patients with anti-CD19 CAR-T relapsed ...